Supporting strategic fundamental research in life sciences through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications.
Abel Garcia-Pino (WELBIO – ULB) and his team shed light on the role played by alarmone for induction of the synthetic activity of E. coli RelA by starved ribosomes.
Abel Garcia-Pino (WELBIO – ULB) and his team uncovered the mechanism of toxicity used by the toxin-antitoxin systems (toxSAS) in bacteria.
From disruptive research of scientific founder Benoit Vanhollebeke (WELBIO - ULB) to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.
WELBIO's essential mission is to support top level fundamental research in life sciences. This mission is currently integrated with the Fonds de la Recherche Fondamentale Stratégique (F.R.S.-FNRS).
WELBIO supports fundamental research with the view to translate scientific results into industrial applications. Through valorisation committees, a sustained focus is kept on the protection of intellectual property in particular.
The WELBIO Bridge Fund is a research funding instrument intended for WELBIO investigators and designed to bridge the gap between early stage research and the development of a competitive package for the next funding step
With its focus on life sciences, WELBIO holds a unique position between fundamental research in all fields and applied biomedical research sur les sciences du vivant. WELBIO works closely with the FRNS and BioWin in particular.
